Cleveland, OH and New York, NY (PRWEB) March 15, 2016 -- Diasome Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing novel, cell targeted therapies for treating diabetes and obesity, and Lyfebulb, LLC, a patient-centric organization with a mission to improve the quality of life for people with chronic disease founded by Karin Hehenberger, MD, PhD, CEO Lyfebulb, Stephen Squinto, PhD, co-founder Alexion, and Riccardo Braglia, CEO Helsinn Healthcare, announced today that they have entered into a collaborative agreement to research and develop Diasome’s proprietary liver targeting nanotechnology systems for improving insulin therapy in people with Type 1 and Type 2 diabetes.
Remarking about this new collaboration, Dr. Hehenberger, Lyfebulb’s Chief Executive Officer, said, “We are excited about Diasome’s late-stage clinical technologies that are designed for the improvement of liver glucose metabolism. This technology has the potential to improve the safety and efficacy of insulin therapy for people with diabetes. We are looking forward to assisting Diasome’s business and scientific teams as these therapies advance in the clinic.” Robert Geho, Diasome’s Chief Executive Officer, stated, “Dr. Hehenberger and her team represent some of the most respected voices in diabetes care and therapeutic development, and they are ideal partners for our projects. Because our companies share the common goal of dramatically changing the manner in which the global problem of diabetes is addressed, this partnership will further strengthen our presence in the diabetes community.”
Lyfebulb is a patient-centric organization whose mission is to improve the quality of life for people living with chronic disease now. Lyfebulb was founded by Dr. Karin Hehenberger, CEO of Lyfebulb, Riccardo Braglia, CEO of Helsinn Healthcare, and Dr. Stephen Squinto, co-founder of Alexion. The Lyfebulb strategy involves partnering with companies aligned with its Mission, growing its online community and creating a powerful event series featuring innovative companies and raising awareness for specific conditions. The Lyfebulb community aims to connect people with chronic disease, inspire them with lifestyle advice and ultimately impact them through its influence on the overall chronic disease and wellness industry. Lyfebulb consulting directly works with select companies that share our vision. For more information, please visit http://www.lyfebulb.com.
Diasome Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. Based on more than thirty years of research and development in the fields of cell receptor targeting, insulin replacement, and hepatic (liver) glucose metabolism, the Company’s pipeline includes multiple injected and oral formulations of liver targeted insulins for both Type 1 and Type 2 diabetic patients that are Phase 3 ready. In addition, Diasome is developing a first-in-class oral compound for the Type 2 diabetes population that is based upon new insights into normal glucose metabolism and a novel mechanism of action, along with a nanotechnology-based oral compound that may have a significant impact in treating obesity. For more information, please visit http://www.diasome.com.
Robert Geho, Diasome Pharmaceuticals, Inc., http://www.diasome.com, +1 216-444-7110, [email protected]
SOURCE Diasome Pharmaceuticals, Inc.